BLyS: The Pivotal Determinant of Peripheral B Cell Selection and Lifespan

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|9|23|1833-1847

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.9, Iss.23, 2003-09, pp. : 1833-1847

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 351-358

Bentham Science Publishers

Access to resources Recommend Favorite

Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 18, Iss. 6, 2018-11 ,pp. : 618-625

Bentham Science Publishers

Access to resources Recommend Favorite

Belimumab: Anti-BLyS Human Monoclonal Antibody, Anti-BLyS Monoclonal Antibody, BmAb, Human Monoclonal Antibody to B-Lymphocyte Stimulator

By Adis International Limited  

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 197-202

Adis International

Access to resources Recommend Favorite

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys

By Jagessar S.  

Journal of Neuroimmune Pharmacology, Vol. 7, Iss. 3, 2012-09 ,pp. : 557-570

Springer Publishing Company

Access to resources Recommend Favorite

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B

By  

Drugs in R&D, Vol. 10, Iss. 1, 2010-05 ,pp. : 55-65

Adis International

Access to resources Recommend Favorite